SGLT2 inhibitors, primarily used for managing type 2 diabetes (T2DM), improve glycemic control and reduce insulin resistance, both of which are implicated in the development of HCC, as shown in the mechanisms summarized in Figure 1. Here, SLC5A2 is linked to hepatocellular carcinoma.